cafepharmaJan 17, 2024
IRA lawsuits will be vital test of US’ ability to regulate pharma market —FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia— Roche racks up phase 3 TIGIT win, but trial design leaves doubts --http://bit.ly/w28kSd #Inflationreductionact #drugpricing #fda #crispr #roche #tigit #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma
Arjan BoltjesJan 11, 2024

"Integrative analysis of #neuroblastoma by single-cell RNA sequencing identifies the #NECTIN2-#TIGIT axis as a target for #immunotherapy"
https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00436-1

Great new work from Judith Wienke et al. from the Molenaar lab in the #PrincessMaximaCenter in #Utrecht.

Great to see this out after seeing it in our group meetings several times. In vivo results sometimes are impressive, but very much in a subgroup it seems. Intriguiging, and curious what underlies this.

#scRNAseq #CancerResearch

Arjan BoltjesJun 23, 2023

"Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma"

Nice new work based on #scRNAseq from our Drost group colleagues at the #PrincessMaximaCenter. a.o., a potential role of #NECTIN3 and #TIGIT in #tumour-induced T cell dysfunction.
https://www.nature.com/articles/s41467-023-38886-8

#OpenAccess
#rhabdomyosarcoma
#immunology #ImmuneSuppression

Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma - Nature Communications

The cellular differentiation states of paediatric rhabdomyosarcoma (RMS) remain to be explored. Here, single-cell RNA sequencing analysis of RMS tumours reveals an immunosuppressive microenvironment and distinct transcriptional programs predictive of patient outcomes.

Nature